10 mai 2013 - FDA responded to a petition and the original formulation of Opana ER (oxymorphone hydrochloride) Extended-Release Tablets was not withdrawn from the market for reasons of safety or effectiveness. As a result, generic versions of the original formulation can continue to be approved and marketed.
Ajouté au bande de temps:
Date:
10 mai 2013
Maintenaint
~ Il y a 12 ans